(Q36611050)

English

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study

scientific article published on 7 August 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

multicenter clinical trial

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

G Verset

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

C Verslype

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

H Reynaert

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

I Borbath

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

P Langlet

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A Vandebroek

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Peeters

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

G Houbiers

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

S Francque

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Arvanitakis

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

J-L Van Laethem

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

7 August 2007

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

97

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

582-588

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Systemic therapy for advanced hepatocellular carcinoma: a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Hepatocellular carcinoma: present status and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

The IGF axis and hepatocarcinogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Regulatory peptide receptors in human hepatocellular carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

30 September 2017

Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

28 June 2018

Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

28 June 2018

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

28 June 2018

Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

28 June 2018

A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

The role of sandostatin LAR in treating patients with advanced hepatocellular cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

Treatment of hepatocellular carcinoma with long acting somatostatin analogues.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

20 September 2018

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360361

4 December 2018

Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme)

1 reference

https://pubmed.ncbi.nlm.nih.gov/17687341

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17687341

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17687341

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/17687341

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[New guidelines to evaluate the response to treatment in solid tumors]

1 reference

https://pubmed.ncbi.nlm.nih.gov/17687341

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue

1 reference

https://pubmed.ncbi.nlm.nih.gov/17687341

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/17687341

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17687341

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6603901

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36611050&oldid=2199085658"